# Jury awards $1.8M in cannabis beverage production dispute with Lift Bridge > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-beverage-production-dispute-1-8m-damages/ > **Published:** 2026-04-01T06:03:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:33:09-04:00 > **Clinical Summary:** A cannabis beverage production dispute resulted in a $1.8M damages award, highlighting legal and quality issues in therapeutic cannabis manufacturing. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ManufacturingQuality ControlLegal IssuesProduct AccessBeverages Why This Matters Legal disputes in cannabis manufacturing affect product availability, quality control standards, and pricing for therapeutic cannabis beverages that patients may rely upon for consistent dosing. Manufacturing disruptions can compromise [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to products with established therapeutic profiles. Clinical Summary A jury awarded $1.8 million in damages against Lift Bridge in a cannabis beverage production dispute, though specific details of the manufacturing or quality issues involved are not provided in the available summary. Cannabis beverages represent a growing segment of therapeutic products, offering precise dosing and controlled onset profiles compared to other delivery methods. Legal and manufacturing disputes in this space can impact product consistency and market availability. Dr. Caplan’s Take “Without knowing the specifics of what went wrong in production, this reminds me why I always counsel patients about supply chain reliability when considering any cannabis therapeutic regimen. Manufacturing disputes signal potential quality control issues that directly affect patient outcomes.” Clinical Perspective 🧠 Clinicians should be aware that legal disputes involving cannabis manufacturers may indicate underlying quality or supply issues. When patients report inconsistent effects from branded cannabis products, manufacturing problems could be a contributing factor. Consider discussing backup therapeutic options with patients who rely on specific cannabis beverage formulations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Jury%20decides%20Lift%20Bridge%20should%20pay%20%241.8M%20in%20damages%20in%20cannabis%20beverage%20produc...%20%40drcaplan&url=https%3A//www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Jury%20decides%20Lift%20Bridge%20should%20pay%20%241.8M%20in%20damages%20in%20cannabis%20beverage%20produc...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/](https://www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What are the main topic areas covered in this cannabis-related update?](#What_are_the_main_topic_areas_covered_in_this_cannabis-related_update) - [Why is this information considered clinically relevant for healthcare providers?](#Why_is_this_information_considered_clinically_relevant_for_healthcare_providers) - [What does the “Notable Clinical Interest” designation mean?](#What_does_the_8220Notable_Clinical_Interest8221_designation_mean) - [How do legal issues and product access relate to clinical cannabis practice?](#How_do_legal_issues_and_product_access_relate_to_clinical_cannabis_practice) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What are the main topic areas covered in this cannabis-related update? The article covers four key areas: Manufacturing, Quality Control, Legal Issues, and Product Access. These topics represent critical aspects of the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) that impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### Why is this information considered clinically relevant for healthcare providers? Cannabis-related manufacturing and quality control developments directly affect patient safety and treatment efficacy. Healthcare providers need to stay informed about these changes to make evidence-based recommendations and ensure [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to quality products. #### What does the “Notable Clinical Interest” designation mean? This designation indicates that while the information may not require immediate action, it represents important developments in the cannabis field. Healthcare professionals should monitor these trends as they may influence future clinical practice or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) protocols. #### How do legal issues and product access relate to clinical cannabis practice? Legal developments affect patient access to [cannabis therapies](https://cedclinic.com/deep-reading-decline-digital-age-insights/) and influence prescribing practices. Changes in regulations or product availability can directly impact treatment options and patient outcomes in clinical settings. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Jury decides Lift Bridge should pay $1.8M in damages in cannabis beverage production case”, “url”: “https://www.twincities.com/2026/03/31/jury-decides-lift-bridge-should-pay-1-8m-in-damages-in-cannabis-beverage-production-case/”, “datePublished”: “2026-04-01T08:35:54Z”, “about”: “jury decides lift bridge should pay”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Stillwater's Lift Bridge Brewery owes $1.8M in THC drink dispute – Star Tribune](https://cedclinic.com/hemp-derived-thc-beverage-regulation-dispute/) Detailed coverage of the $1.8 million damages awarded in the Lift Bridge THC beverage dispute, providing context on legal and manufacturing challenges. [Read the full story](https://cedclinic.com/hemp-derived-thc-beverage-regulation-dispute/) [Lighting science and advanced cultivation to take center stage at Dutch cannabis research tour](https://cedclinic.com/lighting-science-advanced-cultivation-dutch-cannabis-research/) Explore innovations in [cannabis cultivation](https://cedclinic.com/growing-medical-marijuana-at-home-guide/) and how advanced science supports product quality and consistency in therapeutic cannabis. [Learn about cultivation advances](https://cedclinic.com/lighting-science-advanced-cultivation-dutch-cannabis-research/) The sobering reality of CT's cannabis market (opinion) – Hartford Business Journal An opinion piece discussing market challenges and regulatory impacts on cannabis product availability and quality in Connecticut. Explore market insights ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).